Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

18.74 -0.03 (-0.16%)
Official Closing Price Updated: 7:00 PM EDT, Apr 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
News headline image
Ovarian Cancer Player ImmunoGen Can Potentially Be Attractive M&A Target: JP Morgan ↗
JP Morgan upgraded ImmunoGen Inc (NASDAQ: IMGN) from Neutral to Overweight with a price target of $22, up from $9, based on insights gathered from a recent physician survey, which focused on the... 
Via Benzinga
News headline image
Takeda Commits Over $30 Million in Five New Global CSR Partnerships To Further Drive Health Impact in 92 Countries
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
(TAK) - Analyzing Takeda Pharmaceutical's Short Interest ↗
 
Via Benzinga
News headline image
Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a Highly Selective Oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
ImmunoGen Inks Pact With Takeda To Develop ELAHERE Ovarian Cancer Drug In Japan ↗
ImmunoGen, Inc. (NASDAQ: IMGN) inked pacts with Takeda Pharmaceutical Company Limited (NYSE: TAK) to develop and  
Via Benzinga
Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris ↗
Via The Motley Fool
News headline image
2 Ultra-Cheap High-Yield Dividend Stocks to Buy Now ↗
These two high-yield dividend stocks are attractive buys right now. 
Via The Motley Fool
News headline image
How Is The Market Feeling About Takeda Pharmaceutical? ↗
 
Via Benzinga
News headline image
(TAK) - Analyzing Takeda Pharmaceutical's Short Interest ↗
 
Via Benzinga
News headline image
(TAK) - Analyzing Takeda Pharmaceutical's Short Interest ↗
 
Via Benzinga
News headline image
Why Are Poseida Therapeutics Shares Moving Higher Today? ↗
Poseida Therapeutics Inc (NASDAQ: PSTX) shares are trading higher after the company received a $50 million strategic investment by Astellas Pharma Inc (OTC: ALMPY) (OTC: 
Via Benzinga
News headline image
Takeda Reports Strong First Quarter FY2023 Results, Driven by Growth & Launch Products
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
The New England Journal of Medicine Publishes Data from Phase 2 Study of First Oral Orexin Receptor 2 Agonist TAK-994 in Patients with Narcolepsy Type 1
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Disney Considers Different Strategies For Star India, Broadcom Wins Conditional European Approval For VMware Deal, Google Deprioritizes Gen Z Chatbot App: Today's Top Stories ↗
Wall Street Journal 
Via Benzinga
News headline image
Takeda Withdraws FDA Application For Dengue Vaccine Candidate On Data Disagreement ↗
Takeda Pharmaceutical Co Ltd (NYSE: TAK) said on Tuesday that it was voluntarily  
Via Benzinga
News headline image
Week In Review: Billion Dollar Deals - Moderna’s Shanghai Investment And F-Star’s Takeda Collaboration ↗
F-star Therapeutics formed a license agreement with Takeda to develop Fcab domains aimed at undisclosed immuno-oncology targets. Also, Brii Bio signed a global license to an HBV immunotherapeutic... 
Via Talk Markets
News headline image
Pivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK-755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
ADHD Medication Shortage Worsens, Vyvanse Supply Dwindles Amid Adderall Scarcity ↗
The supply of an alternative to Adderall, Vyvanse (lisdexamfetamine), a commonly used medication for Attention-deficit/hyperactivity disorder (ADHD), is dwindling, further limiting options for patients... 
Via Benzinga
News headline image
Argenx's Vyvgart Hytrulo Becomes First FDA Approved Subcutaneous Option For Generalized Myasthenia Gravis ↗
The FDA has approved Argenx SE's (NASDAQ: ARGX) Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), an injection for subcutaneous (SC) use for generalized myasthenia gravis (gMG) in adult... 
Via Benzinga
News headline image
Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
3 AI Stocks That Could Skyrocket Your Wealth ↗
AI is poised to greatly increase the top and bottom lines of many companies, making many AI stocks very attractive at this point. 
Via InvestorPlace
News headline image
HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Takeda and HUTCHMED Announce Publication of Phase 3 FRESCO-2 Results in The Lancet
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Seagen's Adcetris/Immunotherapy Combo Achieves 98% Overall Response Rate in Early-Stage Lymphoma Setting ↗
Seagen Inc (NASDAQ: SGEN) announced updated efficacy and safety results from Part C of phase 2 single-arm trial of Adcetris (brentuximab vedotin) combined with nivolumab and standard chemotherapy... 
Via Benzinga
News headline image
3 Stocks That Could Skyrocket by This Time Next Summer ↗
The best stocks to skyrocket in June have all done well in 2023 and over the past year. They definitely ought to be on your watchlist. 
Via InvestorPlace
News headline image
Why Shares of Innate Pharma Jumped Thursday ↗
The company's collaboration agreement with Sanofi could soon pay off. 
Via The Motley Fool
News headline image
Takeda to Present Oncology Portfolio and Pipeline Data at the 2023 ASCO Annual Meeting and EHA Congress
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
From Takeda Pharmaceutical Company Limited
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.